Drug Profile
Research programme: viral vaccines - GenPhar
Alternative Names: Dengue vaccine (CAdVax-DenTV) - GenPharLatest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator GenPhar
- Class Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Dengue; Hepatitis C; HIV-1 infections; West Nile virus infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Dengue in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Hepatitis-C in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in HIV-1-infections in USA (Parenteral)